{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:15:35Z","timestamp":1792512935587,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T00:00:00Z","timestamp":1625875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T00:00:00Z","timestamp":1625875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s10557-021-07224-9","type":"journal-article","created":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T05:02:30Z","timestamp":1625893350000},"page":"525-532","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Why Not Dipyridamole: a Review of Current Guidelines and Re-evaluation of Utility in the Modern Era"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2990-106X","authenticated-orcid":false,"given":"Mahmoud","family":"Allahham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Atar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Birnbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,10]]},"reference":[{"issue":"4","key":"7224_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1046\/j.1365-2125.1998.t01-1-00677.x","volume":"45","author":"CR Gibbs","year":"1998","unstructured":"Gibbs CR, Lip GY. Do we still need dipyridamole? Br J Clin Pharmacol. 1998;45(4):323\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"7224_CR2","doi-asserted-by":"publisher","first-page":"s39","DOI":"10.1161\/ATVBAHA.107.160226","volume":"28","author":"HH Kim","year":"2008","unstructured":"Kim HH, Liao JK. Translational therapeutics of dipyridamole. Arterioscler Thromb Vasc Biol. 2008;28(3):s39\u201342.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"7224_CR3","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s12350-015-0387-x","volume":"23","author":"MJ Henzlova","year":"2016","unstructured":"Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ. ASNC imaging guidelines for SPECT nuclear cardiology procedures: stress, protocols, and tracers [published correction appears in J Nucl Cardiol 2016 Jun;23(3):640\u20132]. J Nucl Cardiol. 2016;23(3):606\u201339.","journal-title":"J Nucl Cardiol"},{"issue":"2","key":"7224_CR4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/0735-1097(91)90604-8","volume":"18","author":"JD Rossen","year":"1991","unstructured":"Rossen JD, Quillen JE, Lopez JG, Stenberg RG, Talman CL, Winniford MD. Comparison of coronary vasodilation with intravenous dipyridamole and adenosine. J Am Coll Cardiol. 1991;18(2):485\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"9523","key":"7224_CR5","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(06)68734-5","volume":"367","author":"PH Halkes","year":"2006","unstructured":"Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367(9523):1665\u201373.","journal-title":"Lancet"},{"issue":"5627","key":"7224_CR6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1136\/bmj.4.5627.366","volume":"4","author":"AE Gent","year":"1968","unstructured":"Gent AE, Brook CGD, Foley TH, Miller TN. Dipyridamole: a controlled trial of its effect in acute myocardial infarction. Bmj. 1968;4(5627):366\u20138.","journal-title":"Bmj"},{"issue":"3","key":"7224_CR7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1161\/01.CIR.62.3.449","volume":"62","author":"Persantine and aspirin in coronary heart disease","year":"1980","unstructured":"Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation. 1980;62(3):449\u201361.","journal-title":"Circulation"},{"issue":"2","key":"7224_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0735-1097(86)80489-2","volume":"7","author":"CR Klimt","year":"1986","unstructured":"Klimt CR, Knatterud GL, Stamler J, Meier P. Persantine-aspirin reinfarction study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol. 1986;7(2):251\u201369.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"7224_CR9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/0002-9149(90)90804-A","volume":"65","author":"NJ Lembo","year":"1990","unstructured":"Lembo NJ, Black AJ, Roubin GS, et al. Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol. 1990;65(7):422\u20136.","journal-title":"Am J Cardiol"},{"issue":"7329","key":"7224_CR10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","unstructured":"Antithrombotic Trialists\u2019 Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [published correction appears in BMJ 2002 Jan 19;324(7330):141]. BMJ. 2002;324(7329):71\u201386.","journal-title":"BMJ"},{"key":"7224_CR11","doi-asserted-by":"crossref","unstructured":"Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. Circulation. 2012;126(25).","DOI":"10.1161\/CIR.0b013e318277d6a0"},{"key":"7224_CR12","doi-asserted-by":"crossref","unstructured":"Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA\/ACC guideline for the management of patients with non\u2013ST-elevation acute coronary syndromes. Circulation. 2014;130(25).","DOI":"10.1161\/CIR.0000000000000134"},{"key":"7224_CR13","doi-asserted-by":"crossref","unstructured":"Anderson JL, Adams CD, Antman EM, et al. ACC\/AHA 2007 guidelines for the management of patients with unstable angina\/non\u2013ST-elevation myocardial infarction. Circulation. 2007;116(7).","DOI":"10.1161\/CIRCULATIONAHA.107.181940"},{"issue":"7","key":"7224_CR14","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1161\/CIR.0b013e318256f1e0","volume":"126","author":"H Jneid","year":"2012","unstructured":"Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF\/AHA focused update of the guideline for the management of patients with unstable angina\/non\u2013ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update). Circulation. 2012;126(7):875\u2013910.","journal-title":"Circulation"},{"key":"7224_CR15","unstructured":"O\u2019Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction. Circulation. 2013;127(4)."},{"issue":"5","key":"7224_CR16","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1161\/01.CIR.0000134791.68010.FA","volume":"110","author":"EM Antman","year":"2004","unstructured":"Antman EM, Anbe DT, Armstrong PW, et al. ACC\/AHA guidelines for the management of patients with ST-elevation myocardial infarction\u2014executive summary. Circulation. 2004;110(5):588\u2013636.","journal-title":"Circulation"},{"issue":"9","key":"7224_CR17","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1161\/01.CIR.100.9.1016","volume":"100","author":"TJ Ryan","year":"1999","unstructured":"Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC\/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations. Circulation. 1999;100(9):1016\u201330.","journal-title":"Circulation"},{"key":"7224_CR18","doi-asserted-by":"crossref","unstructured":"Becker RC, Meade TW, Berger PB, et al. The primary and secondary prevention of coronary artery disease.\u00a0Chest. 2008;133(6).","DOI":"10.1378\/chest.08-0685"},{"issue":"29","key":"7224_CR19","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2016;37(29):2315\u201381.","journal-title":"European Heart Journal"},{"issue":"2","key":"7224_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119\u201377.","journal-title":"Eur Heart J"},{"issue":"14","key":"7224_CR21","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"J-P Collet","year":"2020","unstructured":"Collet J-P, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal. 2020;42(14):1289\u2013367.","journal-title":"European Heart Journal"},{"issue":"5","key":"7224_CR22","doi-asserted-by":"publisher","first-page":"484","DOI":"10.2183\/pjab.86.484","volume":"86","author":"A Endo","year":"2010","unstructured":"Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(5):484\u201393.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"7","key":"7224_CR23","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0735-1097(99)00440-4","volume":"34","author":"Y Ueda","year":"1999","unstructured":"Ueda Y, Kitakaze M, Komamura K, et al. Pravastatin restored the infarct size-limiting effect of ischemic preconditioning blunted by hypercholesterolemia in the rabbit model of myocardial infarction. J Am Coll Cardiol. 1999;34(7):2120\u20135.","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"7224_CR24","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1161\/01.CIR.0000143830.59419.73","volume":"110","author":"S Sanada","year":"2004","unstructured":"Sanada S, Asanuma H, Minamino T, et al. Optimal windows of statin use for immediate infarct limitation. Circulation. 2004;110(15):2143\u20139.","journal-title":"Circulation"},{"key":"7224_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mvr.2016.04.006","volume":"107","author":"T Obata","year":"2016","unstructured":"Obata T, Nakashima M. Fluvastatin, an HMG-CoA reductase inhibitor, facilitate adenosine production in the rat hearts via activation of ecto-5\u2032-nucleotidase. Microvasc Res. 2016;107:1\u20135.","journal-title":"Microvasc Res"},{"issue":"4","key":"7224_CR26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s10557-008-6105-z","volume":"22","author":"Y Ye","year":"2008","unstructured":"Ye Y, Abu Said GH, Lin Y, et al. Caffeinated coffee blunts the myocardial protective effects of statins against ischemia-reperfusion injury in the rat. Cardiovasc Drugs Ther. 2008;22(4):275\u201382.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"7224_CR27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1749-6632.2010.05725.x","volume":"1207","author":"Y Ye","year":"2010","unstructured":"Ye Y, Perez-Polo JR, Birnbaum Y. Protecting against ischemia-reperfusion injury: antiplatelet drugs, statins, and their potential interactions. Ann N Y Acad Sci. 2010;1207(1):76\u201382.","journal-title":"Ann N Y Acad Sci"},{"key":"7224_CR28","doi-asserted-by":"crossref","unstructured":"Ye Y, Lin Y, Perez-Polo R, et al. Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination. Am J Physiol Heart Circ Physiol. 2007;293(1).","DOI":"10.1152\/ajpheart.00210.2007"},{"issue":"3","key":"7224_CR29","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ijcard.2014.08.013","volume":"176","author":"VM Figueredo","year":"2014","unstructured":"Figueredo VM, Okusa C, Kaneda K, Inamura Y, Miyamae M. Regular dipyridamole therapy produces sustained protection against cardiac ischemia\u2013reperfusion injury: is it time to revisit PARIS? Int J Cardiol. 2014;176(3):822\u20137.","journal-title":"Int J Cardiol"},{"issue":"5\u20136","key":"7224_CR30","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10557-010-6252-x","volume":"24","author":"Y Ye","year":"2010","unstructured":"Ye Y, Long B, Qian J, Perez-Polo JR, Birnbaum Y. Dipyridamole with low-dose aspirin augments the infarct size-limiting effects of simvastatin. Cardiovasc Drugs Ther. 2010;24(5\u20136):391\u20139.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"7224_CR31","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1161\/ATVBAHA.108.179622","volume":"29","author":"P Meijer","year":"2009","unstructured":"Meijer P, Oyen WJ, Dekker D, et al. Rosuvastatin increases extracellular adenosine formation in humans in vivo. Arterioscler Thromb Vasc Biol. 2009;29(6):963\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"7224_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.clpt.2005.03.003","volume":"78","author":"N Riksen","year":"2005","unstructured":"Riksen N, Oyen W, Ramakers B, et al. Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. Clin Pharmacol Ther. 2005;78(1):52\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"7224_CR33","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/j.1527-5299.2007.06047.x","volume":"13","author":"M Akhtar","year":"2007","unstructured":"Akhtar M, Ordovas K, Martin A, Higgins CB, Michaels AD. Effect of chronic sustained-release dipyridamole on myocardial blood flow and left ventricular function in patients with ischemic cardiomyopathy. Congest Heart Fail. 2007;13(3):130\u20135.","journal-title":"Congest Heart Fail"},{"issue":"10","key":"7224_CR34","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1291\/hypres.30.913","volume":"30","author":"S Sanada","year":"2007","unstructured":"Sanada S, Asanuma H, Koretsune Y, et al. Long-term oral administration of dipyridamole improves both cardiac and physical status in patients with mild to moderate chronic heart failure: a prospective open-randomized study. Hypertens Res. 2007;30(10):913\u20139.","journal-title":"Hypertens Res"},{"issue":"6","key":"7224_CR35","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1152\/japplphysiol.00546.2006","volume":"101","author":"EA Martin","year":"2006","unstructured":"Martin EA, Nicholson WT, Eisenach JH, Charkoudian N, Joyner MJ. Influences of adenosine receptor antagonism on vasodilator responses to adenosine and exercise in adenosine responders and nonresponders. J Appl Physiol. 2006;101(6):1678\u201384.","journal-title":"J Appl Physiol"},{"issue":"2","key":"7224_CR36","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/0002-8703(92)90658-I","volume":"123","author":"Y Koga","year":"1992","unstructured":"Koga Y, Kihara K, Yamaguchi R, Wada T, Toshima H. Therapeutic effect of oral dipyridamole on myocardial perfusion and cardiac performance in patients with hypertrophic cardiomyopathy. Am Heart J. 1992;123(2):433\u20138.","journal-title":"Am Heart J"},{"issue":"6","key":"7224_CR37","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s10557-012-6409-x","volume":"26","author":"Y Birnbaum","year":"2012","unstructured":"Birnbaum Y, Castillo AC, Qian J, et al. Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus. Cardiovasc Drugs Ther. 2012;26(6):445\u201356.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7224_CR38","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/TCRM.S152369","volume":"14","author":"MJ Kubisa","year":"2018","unstructured":"Kubisa MJ, Jezewski MP, Gasecka A, Siller-Matula JM, Postu\u0142a M. Ticagrelor - toward more efficient platelet inhibition and beyond. Ther Clin Risk Manag. 2018;14:129\u201340.","journal-title":"Ther Clin Risk Manag"},{"issue":"5\u20136","key":"7224_CR39","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10557-017-6763-9","volume":"31","author":"Y Ye","year":"2017","unstructured":"Ye Y, Nylander S, Birnbaum Y. Unraveling the interaction of aspirin, ticagrelor, and rosuvastatin on the progression of atherosclerosis and inflammation in diabetic mice. Cardiovasc Drugs Ther. 2017;31(5\u20136):489\u2013500.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"7224_CR40","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10557-016-6701-2","volume":"30","author":"Y Birnbaum","year":"2016","unstructured":"Birnbaum Y, Birnbaum GD, Birnbaum I, Nylander S, Ye Y. Ticagrelor and rosuvastatin have additive cardioprotective effects via adenosine. Cardiovascular Drugs and Therapy. 2016;30(6):539\u201350.","journal-title":"Cardiovascular Drugs and Therapy"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07224-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-021-07224-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07224-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:56:10Z","timestamp":1744167370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-021-07224-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,10]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["7224"],"URL":"https:\/\/doi.org\/10.1007\/s10557-021-07224-9","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,10]]},"assertion":[{"value":"29 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mahmoud Allahham, MD: None.Amir Lerman, MD: consulting fee\u2014Philips\/Volcano and Itamar medical.Dan Atar, MD: None.Yochai Birnbaum, MD: research grant\u2014AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}